Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis.

[1]  Takashi Nakamura,et al.  Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. , 2022, Advanced drug delivery reviews.

[2]  M. Younis,et al.  Biomedical Applications of Quantum Dots: Overview, Challenges, and Clinical Potential , 2022, International journal of nanomedicine.

[3]  Yuhua Li,et al.  Advances in COVID-19 mRNA vaccine development , 2022, Signal Transduction and Targeted Therapy.

[4]  K. McCommis,et al.  Hepatic stellate cells in physiology and pathology , 2022, The Journal of physiology.

[5]  H. Harashima,et al.  Clinical Translation of Nanomedicines: Challenges, Opportunities, and Keys. , 2021, Advanced drug delivery reviews.

[6]  Tinghong Ye,et al.  Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy , 2021, Frontiers in Cell and Developmental Biology.

[7]  R. Langer,et al.  Lipid nanoparticles for mRNA delivery , 2021, Nature Reviews Materials.

[8]  T. Satoh,et al.  Engineered ε-decalactone lipomers bypass the liver to selectively in vivo deliver mRNA to the lungs without targeting ligands. , 2021, Materials horizons.

[9]  D. Häussinger,et al.  Hepatic stellate cells: current state and open questions , 2021, Biological chemistry.

[10]  W. Jiskoot,et al.  mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability , 2021, International Journal of Pharmaceutics.

[11]  R. Pettigrew,et al.  The Limitless Future of RNA Therapeutics , 2021, Frontiers in Bioengineering and Biotechnology.

[12]  I. Khalil,et al.  Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[13]  I. Khalil,et al.  Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Tokeshi,et al.  The use of design of experiments with multiple responses to determine optimal formulations for in vivo hepatic mRNA delivery. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[15]  I. Khalil,et al.  Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications , 2020, Advanced Therapeutics.

[16]  Lei Yu,et al.  Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Anti-Fibrotic and Anti-Inflammatory Activities. , 2020, ACS nano.

[17]  I. Khalil,et al.  Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids. , 2020, Biological & pharmaceutical bulletin.

[18]  C. Foged,et al.  Opportunities and Challenges in the Delivery of mRNA-Based Vaccines , 2020, Pharmaceutics.

[19]  M. Manoharan,et al.  The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs , 2019, Nature Nanotechnology.

[20]  M. Tokeshi,et al.  Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles. , 2019, Acta biomaterialia.

[21]  I. Khalil,et al.  Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Mansoor Amiji,et al.  The role of apolipoprotein- and vitronectin-enriched protein corona on lipid nanoparticles for in vivo targeted delivery and transfection of oligonucleotides in murine tumor models. , 2019, Nanoscale.

[23]  I. Khalil,et al.  A Multifunctional Lipid-based Nanodevice for the Highly-specific Co-delivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. , 2019, Molecular pharmaceutics.

[24]  I. Khalil,et al.  A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[25]  P. McKay,et al.  Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA , 2019, Gene Therapy.

[26]  Jinhang Zhang,et al.  An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[27]  A. Pfeiffer,et al.  Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation , 2019, Immunity & Ageing.

[28]  Daniel G Anderson,et al.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  M. Tokeshi,et al.  Understanding structure‐activity relationships of pH‐sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[30]  I. Khalil,et al.  Lung‐Endothelium‐Targeted Nanoparticles Based on a pH‐Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer , 2019, Advanced Functional Materials.

[31]  H. Harashima,et al.  Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting , 2018, International journal of nanomedicine.

[32]  O. Ichii,et al.  An experimental study of menopause induced by bilateral ovariectomy and mechanistic effects of mesenchymal stromal cell therapy on the parotid gland of a rat model. , 2018, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[33]  N. Basset-Seguin,et al.  Vismodegib: A Review in Advanced Basal Cell Carcinoma , 2018, Drugs.

[34]  Manabu Tokeshi,et al.  Development of the iLiNP Device: Fine Tuning the Lipid Nanoparticle Size within 10 nm for Drug Delivery , 2018, ACS omega.

[35]  K. Tomita,et al.  Vitamin A‐coupled liposome system targeting free cholesterol accumulation in hepatic stellate cells offers a beneficial therapeutic strategy for liver fibrosis , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[36]  J. Bolen,et al.  Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey , 2018, Veterinary pathology.

[37]  M. Kohara,et al.  Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell‐mediated lipid nanoparticle‐associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[38]  W. Ling,et al.  Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling , 2017, Autophagy.

[39]  S. Friedman,et al.  Hepatic stellate cells as key target in liver fibrosis. , 2017, Advanced drug delivery reviews.

[40]  Qin Chen,et al.  PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics , 2017, Molecular medicine reports.

[41]  L. O. Ladeira,et al.  Using carbon nanotubes to deliver genes to hard-to-transfect mammalian primary fibroblast cells , 2017 .

[42]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[43]  Yi-Ping Hu,et al.  Hepatocyte polyploidization and its association with pathophysiological processes , 2017, Cell Death & Disease.

[44]  Shan Liu,et al.  Highly Selective Targeting of Hepatic Stellate Cells for Liver Fibrosis Treatment Using a d-Enantiomeric Peptide Ligand of Fn14 Identified by Mirror-Image mRNA Display. , 2017, Molecular pharmaceutics.

[45]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[46]  H. Shan,et al.  Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging , 2015, EJNMMI Research.

[47]  O. Yokosuka,et al.  MicroRNA-122 Inhibits the Production of Inflammatory Cytokines by Targeting the PKR Activator PACT in Human Hepatic Stellate Cells , 2015, PloS one.

[48]  G. Gerken,et al.  All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver Cells , 2015, PloS one.

[49]  Stefan Tenzer,et al.  Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. , 2015, Biomacromolecules.

[50]  R. Schwabe,et al.  High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers , 2015, Nature Protocols.

[51]  Youngwook Kim,et al.  The effect of N/P ratio on the in vitro and in vivo interaction properties of PEGylated poly[2-(dimethylamino)ethyl methacrylate]-based siRNA complexes. , 2013, Macromolecular bioscience.

[52]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[53]  D. Levorse,et al.  Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: lipid polymorphism, structure-activity relationship, and implications for siRNA delivery. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[54]  S. Friedman,et al.  Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis , 2010, Fibrogenesis & tissue repair.

[55]  F. Fan,et al.  Bioluminescent assays for high-throughput screening. , 2007, Assay and drug development technologies.

[56]  P. Schirmacher,et al.  Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. , 2006, Journal of hepatology.

[57]  I. Khalil,et al.  Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery , 2006, Pharmacological Reviews.

[58]  K. Miyajima,et al.  Physical States of Surface and Core Lipids in Lipid Emulsions and Apolipoprotein Binding to the Emulsion Surface* , 1996, The Journal of Biological Chemistry.

[59]  J. Ladero,et al.  Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[60]  S. Friedman,et al.  Chapter 6 – Liver fibrogenesis: Mechanisms and clinical relevance , 2012 .